Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 198.47 USD 2.65% Market Closed
Market Cap: 351.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+48%
Revenue
Forecast
+14%
Operating Income
Forecast
+5%
Net Income
Forecast
+30%

Wall Street
Price Targets

ABBV Price Targets Summary
Abbvie Inc

Wall Street analysts forecast ABBV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABBV is 217.95 USD with a low forecast of 174.73 USD and a high forecast of 263.55 USD.

ABBV Lowest Forecast
Wall Street Target
174.73 USD
12% Downside
ABBV Average Forecast
Wall Street Target
217.95 USD
10% Upside
ABBV Highest Forecast
Wall Street Target
263.55 USD
33% Upside
Lowest
Price Target
174.73 USD
12% Downside
Average
Price Target
217.95 USD
10% Upside
Highest
Price Target
263.55 USD
33% Upside
Abbvie Inc Competitors:
Price Targets
VYGR
Voyager Therapeutics Inc
282% Upside
G
GNFT
Genfit SA
156% Upside
N
4893
Noile-Immune Biotech Inc
210% Upside
BCRX
BioCryst Pharmaceuticals Inc
76% Upside
VYGR
Voyager Therapeutics Inc
282% Upside
G
GNFT
Genfit SA
156% Upside
N
4893
Noile-Immune Biotech Inc
210% Upside
BCRX
BioCryst Pharmaceuticals Inc
76% Upside
300896
Imeik Technology Development Co Ltd
37% Upside
VCEL
Vericel Corp
67% Upside
BPMC
Blueprint Medicines Corp
23% Upside
AZT
Arcticzymes Technologies ASA
11% Upside

Revenue
Forecast

Revenue Estimate
Abbvie Inc

For the last 8 years the compound annual growth rate for Abbvie Inc's revenue is 10%. The projected CAGR for the next 3 years is 7%.

10%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Abbvie Inc

For the last 8 years the compound annual growth rate for Abbvie Inc's operating income is 7%. The projected CAGR for the next 3 years is 29%.

7%
Past Growth
29%
Estimated Growth
Estimates Accuracy
-31%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Abbvie Inc

For the last 8 years the compound annual growth rate for Abbvie Inc's net income is -4%. The projected CAGR for the next 3 years is 87%.

-4%
Past Growth
87%
Estimated Growth
Estimates Accuracy
-53%
Average Miss
What are analyst estimates?

See Also

Summary
ABBV intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBV stock valuation using valuation multiples.
Wall Street Estimates
ABBV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABBV's stock price target?
Price Target
217.95 USD

According to Wall Street analysts, the average 1-year price target for ABBV is 217.95 USD with a low forecast of 174.73 USD and a high forecast of 263.55 USD.

What is Abbvie Inc's Revenue forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Abbvie Inc's revenue is 10%. The projected CAGR for the next 3 years is 7%.

What is Abbvie Inc's Operating Income forecast?
Projected CAGR
29%

For the last 8 years the compound annual growth rate for Abbvie Inc's operating income is 7%. The projected CAGR for the next 3 years is 29%.

What is Abbvie Inc's Net Income forecast?
Projected CAGR
87%

For the last 8 years the compound annual growth rate for Abbvie Inc's net income is -4%. The projected CAGR for the next 3 years is 87%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 252,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.